Form 4: Cartesian Therapeutics CEO Sells Shares to Cover Tax Obligations

Cartesian Therapeutics CEO, Carsten Brunn, sold a total of 17,271 shares of common stock to cover tax obligations and broker fees related to vesting restricted stock units.

Summary

• Carsten Brunn, the President and CEO of Cartesian Therapeutics, sold 8,563 shares of common stock on January 3, 2025, at a price of $16.7219 per share.
• He then sold an additional 8,708 shares on January 6, 2025, at a price of $16.8322 per share.
• These sales were made to satisfy withholding tax obligations and cover broker fees associated with the vesting of restricted stock units.
• Following these transactions, Mr. Brunn's direct ownership of Cartesian Therapeutics common stock decreased to 204,096 shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar sales by executives at other firms.
• The sale prices are within the normal range for the stock, indicating no unusual market activity.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but are not expected to significantly affect shareholders.
• The transactions do not impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Cartesian Therapeutics, Carsten Brunn, stock sale, insider trading, Form 4, restricted stock units, tax obligations